FDA’s approval of Merck & Co. Inc.’s Keytruda (pembrolizumab) in non-small cell lung cancer marks a turning point in development for the family of programmed death inhibitors in that it is the first approval targeted for patients with PD-L1 expression, measured with a new companion diagnostic.
On Oct. 2, the agency granted accelerated approval for Keytruda for patients with advanced (metastatic) NSCLC whose disease has progressed...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?